Overview

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to measure the effects of LGT209 when given intravenously to patients with high cholesterol who are on stable doses of statin medications, and to healthy subjects with elevated cholesterol
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals